Navigation Links
MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
Date:10/1/2007

believes that its sirolimus product may serve as a potentially highly-efficacious therapeutic for a wide range of ocular diseases and conditions, including the treatment and prevention of wet AMD.

As the active pharmaceutical ingredient in the FDA-approved products Rapamune(R) and CYPHER(R) Sirolimus-eluting Coronary Stent, sirolimus has been safely administered to humans for more than six years. MacuSight has developed a proprietary minimally-invasive, sustained administration approach for its novel liquid sirolimus formulation which it believes will provide the product with significant competitive advantages related to convenience, ease-of-use, compliance and safety.

About Diabetic Macular Edema

Diabetic macular edema (DME) is a serious manifestation of diabetic retinopathy that involves retinal swelling brought on by the leaking of fluid from small blood vessels within the macula. As the condition develops, central vision becomes blurred. DME can progress fairly rapidly and over just a few years can lead to permanent visual loss. There is a significant unmet need to both reverse the visual loss associated with DME and to help delay the progression of this condition.

About MacuSight

MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost- effectiveness of its product candidates.

The company's lead development program is centered
'/>"/>

SOURCE MacuSight, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pomerantz LLP is investigating ... ("Vitae" or the "Company") (NASDAQ: VTAE ).  ... Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. ... certain of its officers and/or directors have violated Sections ... 1934.  On February 27, 2015, the ...
(Date:2/27/2015)... Securities lawyers at Dunnam & Dunnam ... (NASDAQ: SLXP ) in connection with a ... are encouraged to contact attorney Hamilton Lindley by ... upon the shareholder value of the transaction. Under terms ... $158.00 per share in cash. At least one analyst ...
(Date:2/27/2015)... 2015 Report Details   ... trends, R&D progress, and predicted revenues ,Where is the ... the commercial prospects for this market and related technologies? ... other trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... Pharmos Corporation (OTC-PINK: PARS) today reported financial results for ... These results are included in the Company,s Quarterly Report on ... Second Quarter Ended June 30, 2011The Company recorded ... for the second quarter 2011 compared to a net loss ...
... Md., Aug. 8, 2011 /PRNewswire-Asia/ -- Chindex International, Inc. ... company providing health care services in China through the operations ... hospitals and affiliated ambulatory clinics, today announced financial results for ... 30, 2011. Second Quarter 2011 ...
Cached Medicine Technology:Pharmos Corporation Reports 2011 Second Quarter Results 2Pharmos Corporation Reports 2011 Second Quarter Results 3Pharmos Corporation Reports 2011 Second Quarter Results 4Pharmos Corporation Reports 2011 Second Quarter Results 5Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 2Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 3Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 4Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 5Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 6Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 7Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 8Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 9Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 10Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 11
(Date:2/28/2015)... 2015 National Sales Solutions ... marketing and supply chain management for consumer packaged ... bringing its award winning solutions for thinning-damaged hair ... are specifically created to combat thinning-damaged hair. ... committed to marrying science with nature to create ...
(Date:2/28/2015)... Kaylie Corrigan, Outdoor Supervisor at ... and current student obtaining her Masters degree in social ... forum in psychoeducation on substance use for teens at ... part of her studies. , “Even though these students ... counseling at the high school and junior high school ...
(Date:2/28/2015)... 2015 The noted Toronto plastic surgeon ... was recently featured in the January/February 2015 issue of ... David Ellis was featured in an article entitled “Get ... enhancements that Kim Cattrall has possibly undergone to maintain ... is smooth without horizontal lines or frown line creases, ...
(Date:2/28/2015)... Plugin creators from Pixel Film Studios ... fully customizable transition pack made specifically for ... users total control over 30 transition presets built exclusively ... Film Studios. “TransFold Volume 2 gives endless possibilities to ... 2 from Pixel Film Studios brings back folding screen ...
(Date:2/28/2015)... 2015 1Heart Caregiver Services CEO ... brand at Houston Texas Franchise Expo South and ... its executive delegates headed by Vice-President of Operations ... Training Randolph Clarito. , Franchise Expo South, sponsored ... February 4-7 and featured Franchise brands of every ...
Breaking Medicine News(10 mins):Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Dr. David Ellis Featured In Elevate Magazine 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3
... CHICAGO, Feb. 26 A lawsuit was filed today ... boy who contracted salmonella poisoning,after eating at a Blueberry ... The child was hospitalized for three days as a ... the Cook County Department of Health,after the Communicable Disease ...
... Feb. 26 CVS Caremark Corporation (NYSE: ... Executive Vice President, Chief Financial Officer and Chief ... investors at the Raymond James Institutional Investors Conference ... to speak at approximately 8:05 a.m. EDT. ...
... Pharmaceutical Association (GPhA) today applauded President Obama,s budget ... biogenerics that will substantially reduce health care costs ... prices. The President,s budget proposal would ensure that ... model, by ensuring that brand companies cannot extend ...
... ATLANTA, Feb. 26, 2009 Arthritis affects more than ... be a substantial barrier to utilizing physical activity to ... Morbidity and Mortality Weekly Report ( MMWR ) ... and Prevention (CDC). According to the Arthritis Foundation, the ...
... in sunscreen, researchers say , , THURSDAY, Feb. 26 (HealthDay News) ... protection from skin cancer, and new research may explain why. ... mechanism by which caffeine is associated with decreased skin cancer," ... dermatology at the University of Washington in Seattle. , For ...
... Congress Must Reform Ineffective 33-year-old Chemicals Law, Expert Testifies ... the nation,s main chemicals law, the Toxic Substances Control ... ensure the safety of the tens of thousands of ... the conclusion of expert testimony provided at a ...
Cached Medicine News:Health News:CVS Caremark Corporation to Present at the Raymond James Institutional Investors Conference on March 10th 2Health News:GPhA Praises President Obama's Support for Safe and Affordable Biogenerics as Critical Solution to America's Ailing Health Care System 2Health News:Arthritis hinders physical activity for adults with heart disease 2Health News:Caffeine May Offer Some Skin Cancer Protection 2Health News:Caffeine May Offer Some Skin Cancer Protection 3Health News:Main U.S. Toxics Law Failing to Ensure Safety of Thousands of Chemicals 2Health News:Main U.S. Toxics Law Failing to Ensure Safety of Thousands of Chemicals 3
The AXIUS™ Blower/Mister provides controlled delivery of CO2 and saline to improve visibility during anastomosis....
The RX HERCULINK® PLUS Biliary Stent System is Guidant's high performance .014" guide wire compatible system. It is available in stent diameters of 4.0-6.5mm for the 12mm stent length and 4.0-7.0...
... Unique triaxial catheter design and ... deployment. Six proprietary radiopaque Nitinol markers ... of the stent enhance visibility. Corrugated ... strength, while the nested ring pattern ...
... left heart catheterization occurs when the initial ... sheath with an alternate curve while maintaining ... exchange has required a repeat septal puncture--complex ... overcome this problem with the unique PERRY ...
Medicine Products: